Job Opportunities - Agilent is hiring a Sales Engineer with a Master's degree in relevant fields such as pharmaceuticals, food, environment, chemistry, biology, or materials, and requires strong communication skills and a willingness to learn [3] - Zhiming Future is looking for a Biological Analysis Instrument Sales Consultant in Shanghai, offering a salary range of 8k-13k, requiring a college degree and three years of sales experience in the biological instrument industry [4] - Beiyu Analysis is seeking Sales Representatives in multiple locations, with salary negotiable [5] - Kailai is hiring an Instrument Sales Engineer with a salary range of 15k-25k, requiring over five years of sales experience and familiarity with ICP-MS technology [7] - Tianmei Yituo is looking for a Sales Engineer in Chongqing, offering a salary of 9k-13k, requiring knowledge of various laboratory instruments [8] - Beifen Ruili is hiring a Sales Engineer in multiple cities, with a salary range of 6k-12k, requiring experience in instrument sales [10] - Yena is seeking a Sales Engineer nationwide, requiring over three years of experience in chemical analysis instruments and fluency in English [11] - Ohaus is hiring a Sales Engineer in Beijing and Nanjing, with a salary range of 11k-18k, focusing on laboratory instrument sales [15] - Steel Research Nack is looking for an ICP System Engineer in Beijing, offering a salary of 25k-30k, requiring a Master's degree and extensive experience in ICP spectrometry [26] Skills and Qualifications - Most positions require a Bachelor's degree or higher in relevant fields such as chemistry, biology, or environmental science [6][9][12] - Strong communication skills, customer service awareness, and the ability to work under pressure are commonly sought after [4][6][10] - Experience in sales, particularly in the laboratory or analytical instrument sector, is a significant advantage [7][11][26] - Many roles require the ability to travel frequently and adapt to various work environments [8][9][18]

Core Viewpoint - The company, Zhongke Meiling Cryogenic Technology Co., Ltd., is utilizing idle funds for cash management, with a maximum investment of 260 million RMB in bank financial products while ensuring operational liquidity and risk control [1] Group 1: Financial Management - The company announced the use of 110 million RMB of idle self-owned funds for cash management, with a remaining balance of 230 million RMB in self-owned financial products [1] - The maximum amount for investment in bank financial products is set at 260 million RMB [1] Group 2: Company Overview - Zhongke Meiling was established in 2002 in Hefei, Anhui Province, and is one of the early entrants in the biological cell ultra-low temperature storage sector [1] - The company specializes in the research, production, and sales of a wide range of low-temperature storage equipment and provides comprehensive solutions in the biomedical field [1] Group 3: Achievements and Recognition - The company is recognized as a high-tech enterprise and a national-level "specialized and innovative" small giant enterprise, receiving numerous awards including the National Technology Invention Award (second prize) and various provincial and municipal honors [2] - The company aims to enhance its core refrigeration technology in the biomedical field and accelerate domestic substitution efforts [2] Group 4: Performance Metrics - In the first three quarters of 2025, the company achieved operating revenue of 224 million RMB, representing a year-on-year growth of 4.75%, and a net profit attributable to shareholders of 12.76 million RMB, with an increase of 8.19% year-on-year [3]

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近 日 ， 石 河 子 大 学 发 布 3 1 项 仪 器 设 备 采 购 意 向 ， 预 算 总 额 达 1 . 4 0 亿 元 ， 涉 及 恒 温 培 养 箱、生物安全柜、落地离心机、酶标仪、高效液相、粒径电位仪、超低温- 8 0 ℃ 冰箱、冷冻干 燥机、小型高速冷冻离心机、超声细胞破碎仪、灭菌锅、超微量分光光度计等，预计采购时间 为2 0 2 5 年 3 月 ~2 0 2 6年3月 。 详细采购清单： | 超 | 滤 | 膜 | 检 | 测 | 器 | 、 | 高 | 压 | 细 | 胞 | 破 | 碎 | 仪 | 、 | 自 | 分 | 离 | 设 | 动 | 电 | 位 | 滴 | 定 | 仪 | 、 | 高 | 效 | 逆 | 流 | 色 | 谱 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - The company emphasizes that technological self-reliance is driving the industry towards domestic production, which further expands its development space and enhances market competitiveness across its four major industries [1] Market Position and Performance - The company's market share in the low-temperature storage industry continues to increase, with a projected market share of over 50% in plasma collection solutions by mid-2025, based on public and third-party bidding data [1] - The company ranks among the top three in the automated medication market and continues to break through in the domestic market for scientific instruments, with its total organic carbon analyzers and UV spectrophotometers being the top two domestic brands [1] - The centrifuge series has entered the top ten in market share among industry brands, while the biological safety cabinet has risen to the number one position nationwide, and the cultivation series maintains the highest market share among domestic brands [1] International Market Presence - Preliminary market research indicates that the company's three major low-temperature product lines hold the leading market share in 25 overseas countries [1]

Core Viewpoint - Beijing Forestry University has announced multiple government procurement intentions for laboratory instruments, with a total budget of 91.11 million yuan, indicating significant investment in research infrastructure [1][2]. Summary by Relevant Sections Procurement Overview - The procurement includes nine categories of laboratory instruments such as elemental analyzers, total organic carbon analyzers, ion chromatographs, multifunctional enzyme markers, and digital PCR systems, with the expected procurement period from May 2025 to February 2026 [2]. Detailed Procurement List - The procurement intentions encompass various equipment for the National Forestry and Grassland Germplasm Resource Preservation Project, including: - Germplasm preservation containers for long-term use in low-temperature storage [4]. - Experimental tables, biological safety cabinets, and sterilization equipment for laboratories, requiring scientific design and reliable quality [4]. - A liquid nitrogen preservation system for ultra-low temperature storage, emphasizing excellent system performance and stability [4]. - Walk-in plant growth chambers and tissue culture racks with specific design and lighting requirements [4]. - Automated handling robots for the efficient transfer of germplasm resources and experimental materials, designed to integrate seamlessly with automated storage systems [5].

Core Viewpoint - The narrative of Chinese companies going global is evolving from "going out" to "going in," with Haier Biomedical leading this transformation through a focus on technology, localization, and ecosystem collaboration [1][2]. Group 1: Strategic Shift - Haier Biomedical's globalization is characterized by a systematic strategic elevation, moving beyond mere product competition to a multidimensional contest involving scenario innovation, local responsiveness, and ecosystem integration [2]. - The company aims to transition from being a "product supplier" to a "solution co-builder" by establishing localized centers for marketing, logistics, and after-sales service [3]. Group 2: Localization Strategy - The "one country, one policy" localization strategy is essential for true globalization, allowing Haier Biomedical to respect market differences and tailor solutions to local needs [3]. - Recent collaborations with top-tier institutions and strategic partnerships in various countries demonstrate the effectiveness of this localized approach, leading to increased recognition and repeat purchases from overseas clients [3]. Group 3: Ecosystem Collaboration - Haier Biomedical's presence in over 160 countries with more than 1,100 partners reflects its strategic vision of building a "zero-boundary ecosystem," enhancing its competitive edge from "product power" to "platform power" [4]. - The shift towards ecosystem collaboration allows global partners to become a community of shared interests, collectively taking on market responsibilities and sharing innovation outcomes [6]. Group 4: Future Directions - The company's practices indicate that Chinese enterprises' globalization has entered a "deep water zone," where success hinges on ecosystem-building capabilities, depth of local integration, and efficiency in global resource allocation [6]. - For Chinese medical companies to secure a significant position in the global landscape, they must move beyond a singular focus on manufacturing advantages to a comprehensive strategy that includes technology, scenarios, and ecosystems [6].

Core Viewpoint - Haier Biomedical has shown significant performance recovery in Q3 2025, driven by strong revenue growth and improved profitability, indicating a positive trend in the life sciences and medical device sectors as they transition towards international expansion and technological innovation [1][2]. Group 1: Financial Performance - In Q3 2025, Haier Biomedical achieved a revenue of 566 million yuan, representing a year-on-year increase of 1.24% and a quarter-on-quarter increase of 11.68% [1]. - The net profit attributable to shareholders reached 55.65 million yuan, with a quarter-on-quarter growth exceeding 70% [1]. - The non-recurring net profit was 49.99 million yuan, showing a quarter-on-quarter increase of over 100% [1]. Group 2: Industry Trends - The life sciences sector is entering a new phase of valuation recovery and industrial upgrading after a decade of development, supported by supply clearing, demand recovery, and accelerated domestic substitution [2]. - Haier Biomedical's performance recovery is attributed to revenue growth, business structure upgrades, and enhanced product competitiveness [2]. Group 3: Business Segments - The recovery in Q3 is supported by four key industries: low-temperature storage, smart medication, blood technology, and laboratory solutions, which have begun to show stable performance [3]. - New industries, particularly smart medication and blood technology, have demonstrated significant growth, contributing to approximately 48% of total revenue [3]. - The smart medication segment has established itself among the top three in the automated medication market by addressing hospital drug management challenges [3]. Group 4: Market Position and Innovation - The low-temperature storage segment continues to maintain a leading market share in China, with steady growth in revenue [4]. - Haier Biomedical's commitment to technological innovation is evident in its AI integration and the establishment of a multi-layered AI foundation, enhancing its product offerings and market responsiveness [5][6]. - The company reported a 20.18% year-on-year increase in overseas market revenue, reaching 634 million yuan, with successful localization strategies implemented in 18 countries [6].

Core Viewpoint - The implementation of mandatory national standards for biological safety cabinets aims to enhance detection needs, alongside over a thousand other standards set to take effect in November, which will improve product quality and promote sustainable development [1][2]. Group 1: Overview of New Standards - A total of over a thousand new standards will be implemented in November 2025, covering key sectors such as agriculture, environmental protection, healthcare, petrochemicals, electronics, transportation, and machinery [2][5]. - The release and implementation of these standards are concrete measures to realize the concept of "quality improvement and efficiency enhancement," aimed at driving technological upgrades, quality enhancement, and green transformation across various industries [2][5]. Group 2: Specific Areas of Focus - In the agriculture sector, the focus will be on food safety, disease prevention in plants and animals, water conservation, and genetic resource protection, providing technical support for sustainable agricultural development [5]. - The environmental protection standards emphasize carbon footprint accounting and pollution monitoring, contributing to the achievement of carbon neutrality goals [5]. - In healthcare, the standards will strengthen infectious disease prevention, medical device safety, and elderly care service regulations, reflecting the integration of public health and the construction of a healthy China [5]. - The petrochemical, textile, and mining industries will focus on green processes, material performance, and safety production, promoting the transformation of traditional industries towards high-end, intelligent, and green development [5]. Group 3: Notable Standard - Biological Safety Cabinet - The new standard GB 41918-2022 for biological safety cabinets specifies classifications, requirements, testing methods, labeling, inspection rules, and storage guidelines [6][7].

Investment Rating - The investment rating for the company is "Accumulate" (first coverage) [1][7] Core Viewpoints - The company is a pioneer in the field of ultra-low temperature storage for biological cells in China, backed by Changhong Group and supported by the Chinese Academy of Sciences. It has developed several industry-leading products, including ultra-low temperature storage boxes reaching -180°C, and has a strong patent portfolio with 436 patents as of the end of 2024 [4][7][21]. - The company has shown stable revenue growth, with a projected revenue of 320.91 million yuan in 2025, reflecting an 8.50% increase year-on-year. The net profit is expected to reach 25.22 million yuan, a 39.43% increase [5][7]. - The domestic medical device market is projected to grow significantly, with the market size expected to exceed 1.8 trillion yuan by 2030, and the biological low-temperature storage equipment market is anticipated to grow from 6.772 billion yuan in 2022 to 21.543 billion yuan by 2028 [7][9]. Company Overview - The company, established in 2002, has developed a diverse product portfolio in the ultra-low temperature storage sector, including products that operate in the temperature range of -196°C to 8°C, widely used in medical, research, and biopharmaceutical fields [13][28]. - The company has received numerous accolades, including being recognized as a national-level "specialized and innovative" small giant enterprise and has won various awards for technological innovation [17][21]. Financial Forecast - The financial forecast indicates total revenue of 302.79 million yuan in 2023, with a decline of 25.51%, followed by a slight recovery in 2024 to 295.77 million yuan. The company is expected to achieve a revenue of 320.91 million yuan in 2025, with a growth rate of 8.50% [5][7]. - The projected net profit for 2025 is 25.22 million yuan, representing a significant increase of 39.43% compared to 2024 [5][7]. Industry Analysis - The medical device industry is experiencing rapid growth, driven by various factors, including policy support and increasing demand for domestic medical equipment. The company is well-positioned to benefit from these trends as a leading player in the biological low-temperature storage market [9][28]. - The company has a competitive edge in the market, having ranked among the top three domestic brands in low-temperature storage equipment, and is expected to capture more market share due to its technological advantages [29][40].

Summary of Zhongke Meiling's Conference Call Company Overview - **Company**: Zhongke Meiling - **Period**: First three quarters of 2025 Key Financial Performance - **Revenue**: 224 million CNY, up 4.75% year-on-year [2][3] - **Net Profit**: 12.75 million CNY, up 8.19% year-on-year [2][3] - **Net Profit (Excluding Non-recurring Items)**: 6.54 million CNY, up 146% year-on-year [2][3] - **Profitability**: Enhanced due to cost control and efficiency improvements [2] Industry and Market Dynamics - **Policy Impact**: The national "old-for-new" policy has limited impact on general equipment, mainly driving the renewal of large scientific instruments [2][3] - **Market Adaptation**: Company needs to continuously monitor market changes and adjust sales strategies to adapt to structural demand changes brought by policies [2] Product Performance - **Biological Safety Cabinets**: - New models launched, sales growth accelerated, and gross margin improved [2][4] - Target to increase new product revenue to 30% of total revenue in the next 2-3 years [6] - **Centrifuges**: - Rapid market growth but did not meet expectations [5] - Plans to adjust organizational structure and market strategies to enhance competitiveness [5] - **Overseas Business**: - Significant growth, with over double-digit increase year-on-year expected for the full year [2][8] - Focus on ultra-low temperature products to stabilize overall gross margin [8] Strategic Initiatives - **Automation Projects**: - Identified as a future growth point, with plans to increase R&D investment and accelerate project delivery as technology matures [11][12] - **Cost Control**: - Continuous implementation of cost reduction and efficiency enhancement strategies to maintain gross margin despite price reductions [10] Challenges and Risks - **Market Competition**: - Intense competition in the low-end centrifuge market with around 300 competitors [16] - **Order Delays**: - Recent delays in order delivery due to stricter government funding regulations [19] - **Cash Flow**: - Expected to be positive but lower than last year due to reduced government subsidies [23] Future Outlook - **R&D Investment**: - Plans to increase R&D spending to support automation and new product development [24][25] - **Market Strategy**: - Focus on expanding international market presence, particularly in developed regions, to mitigate domestic uncertainties [21] Additional Insights - **Accounts Receivable**: - Growth mainly from overseas clients, with healthy turnover rates [22] - **Product Demand**: - Anticipated strong demand for refrigerators and centrifuges in Q4, with confidence in achieving growth compared to last year [18] This summary encapsulates the key points from Zhongke Meiling's conference call, highlighting financial performance, market dynamics, product developments, strategic initiatives, challenges, and future outlook.